IXICO Secures £1.5m Contract Extension on Global Phase 2 Huntington’s Trial

IXICO plc (LSE:IXI) has won a contract extension worth approximately £1.5 million tied to an ongoing global Phase 2 clinical trial in Huntington’s disease. The award comes from one of the world’s largest international pharmaceutical groups, reflecting continued progress in the study and reinforcing IXICO’s role in advanced neurological drug development programmes.

The additional work is expected to generate around £1.5 million in revenue for IXICO over the next three years. The extension underscores the company’s long-standing relationships with major biopharma clients and the growing reliance on imaging biomarkers and AI-driven analytics to support decision-making in complex central nervous system trials.

Bram Goorden, CEO of IXICO, commented: “This contract extension is an example of how IXICO’s compelling IXI™ technology platform and neurological disease expertise consistently deliver gold standard outcomes for biopharma customers as they advance drug development in such a devastating neurological disease.”

About IXICO plc

IXICO is a global specialist in neuroscience imaging and biomarker analytics, deploying its proprietary AI-powered IXI™ platform to support the discovery, development and monitoring of treatments for neurological disorders. The company operates as an end-to-end Imaging Contract Research Organisation (iCRO), working with leading pharmaceutical companies, biotech firms, academic consortia and non-profit organisations.

With more than 20 years of experience, IXICO has contributed to hundreds of neurological clinical trials and analysed hundreds of thousands of brain scans. Its platform is purpose-built for neurological disease, processing imaging data from global studies to measure biomarkers linked to the diagnosis, progression and treatment of conditions such as Alzheimer’s, Huntington’s and Parkinson’s disease. By combining advanced analytics with scientific expertise, IXICO aims to reduce variability, enhance reproducibility and translate complex imaging data into clinically meaningful insights.